Providing Accessible and Affordable Rare Disease Medications for the Indian Market.
In an era marked by remarkable technological advancements and unprecedented opportunities, it becomes our societal responsibility to leverage these possibilities. Laurus is deeply committed to this responsibility, and our belief in making Rare Disease Drugs more accessible and affordable stands at the forefront. By introducing medications for unmet therapies, we aim not only to assist patients but also to alleviate the social and economic burden associated with various health conditions in society.
TriLaWil is employed in the treatment of Wilson's disease, a rare inherited disorder characterized by the accumulation of copper in the liver, brain, and other vital organs. Typically diagnosed between the ages of 5 and 35, Wilson’s disease disrupts the normal process of copper absorption from food, leading to its buildup in the body.
Copper plays a crucial role in the development of healthy nerves, bones, collagen, and the skin pigment melanin. In individuals with Wilson's disease, impaired copper elimination through the liver results in life-threatening levels of accumulation. Early diagnosis and treatment are essential for significantly improving the Quality of Life (QOL) for patients.
Lasinone is prescribed for the treatment of Tyrosinemia, also known as tyrosinaemia. Tyrosinemia is an inborn error in metabolism, resulting in the body's inability to break down the amino acid tyrosine. Untreated tyrosinemia can lead to liver and kidney disturbances, and if left unmanaged, it may progress to liver failure.
AMMOBULA is used to Treat Urea cycle disorders (UCDs)
(UCDs) are inborn errors of metabolism resulting from defects in one of the enzymes or transporter molecules involved in the hepatic removal of ammonia from the bloodstream. Removal of ammonia from the bloodstream normally occurs via its conversion to urea, which is then excreted by the kidneys. Consequently, urea cycle disorders lead to an accumulation of ammonia. Ammonia is extremely toxic, particularly to the central nervous system. Newborns with severe mutations in any one of the first four enzymes of the urea cycle can become catastrophically ill within 36 to 48 hours of birth despite appearing normal at birth.
AMMOBULA is a nitrogen-scavenging agent used in the treatment of urea cycle disorders (UCDs). It works by converting to phenylacetic acid (PAA), which then conjugates with glutamine to form phenylacetylglutamine (PAGN), which is excreted in the urine, thus reducing ammonia levels. NaPBA is also known to affect branched-chain amino acid (BCAA) metabolism.
Larglustat is used in the Treatment of Gaucher disease (GD)
Gauchers Disease is a sphingolipidoses, a subgroup of lysosomal storage diseases. It is the most common lysosomal storage disease, having an autosomal recessive inheritance and resulting from a deficiency of the glucocerebrosidase enzyme due to a genetic defect on the glucosylceramidase beta (GBA1) gene. The enzyme deficiency results in the inability to break down glucosylceramide in lysosomes, and lipid-laden macrophages accumulate in the tissues.
Eliglustat is a glucosylceramide synthase inhibitor. It was approved in August 2014 as first-line treatment for the long-term treatment of adults with Gaucher disease type 1. The dose of eliglustat is determined by establishing the patient’s CYP2D6 phenotype (ie, extensive metabolizers [EM], intermediate metabolizers [IM], or poor metabolizers [PM]).